301/697US=14 / Quimioterapia
Herring RA, Hesselgrave J, Norville L, Madsen L. Toxicity and symptom management. In: Kline N. The pediatric chemotherapy and biotherapy curriculum. 2ªed. Glenview: APHON, 2009. p. 89-128. ISBN 978-09666193-17.

TOXICIDADE E DE OUTROS SINTOMAS; SISTEMA HEMATOPOIETICO; ANEMIA; NEUTROPENIA; TROMBOCITOPENIA; SISTEMA DE COAGULACAO; TROMBOSE VENOSA PROFUNDA; ACIDENTE VASCULAR CEREBRAL; SISTEMA IMUNOLOGICO; IMUNOSSUPRESSAO; SISTEMA NERVOSO; CRANIAL DEFICITS DO NERVO; NEUROPATIA PERIFERICA; MUDANCAS CONGNITIVE E COMPORTAMENTAIS; SISTEMA AUDITIVO; OTOTOXICIDADE; OFTALMOLOGICA SISTEMA; CONJUNTIVITE; FOTOFOBIA; SISTEMA ENDOCRINO; INSUFICIENCIA DE INSULINA; DIABETES INSIPIDUS; SINDROME DA SECRECAO INAPROPRIADA DE ADH; PNEUMONITE; EDEMA PULMONAR; SISTEMA CARDIACO; MIOCARDIOPATIA AGUDA; SISTEMA GASTROINTESTINAL; NAUSEAS E VOMITOS; PRISAO DE VENTRE; DIARREIA; QUIMICA DA HEPATITE; DOENCA VENO-OCLUSIVA; PANCREATITE; NUTRICAO ALTERADA; SISTEMA RENAL; COMPROMETIMENTO TUBULO RENAL; SINDROME DE LISE TUMORAL AGUDA; CISTITE HEMORRAGICA; SISTEMA TEGUMENTAR; ALTERACOES DA MUCOSA; ALTERACOES CUTANEAS; EXTRAVASAMENTO; FADIGA GERAL; REACCOES ALERGICAS

302/697US=21 / Patologia
Petersen RO, Sesterhenn IA, Davis CJ. Kidney. In: ___. Urologic pathology. 3rd ed. Philadelphia: Lippincott Willians & Wilkins, 2009. p. 1-131. ISBN 978-0-7817-5343-2.

RIM; RIM. ANATOMIA; RIM. HISTOLOGIA; DISTURBIOS CONGENITOS DO RIM; AGENESIA; HIPOPLASIA DO RIM; HIPOPLASIA RENAL COM OLIGOMEGANEPHRONIA; HIPOPLASIA SEGMENTAR; ECTOPIA RENAL CONGENITA; RIM SUPRANUMERARIO; ROTACAO ANOMALA; RIM EM FERRADURA; DOENCAS CISTICAS; RIM DISPLASICO MULTICISTICO; DOENCA RENAL POLICISTICA AUTOSSOMICA DOMINANTE; DOENCA RENAL POLICISTICA AUTOSSOMICA RECESSIVA; COMPLEXO DE DOENCA CISTICA MEDULAR; DOENCA DE VON HIPPEL-LINDAU; ESCLEROSE TUBEROSA; RIM ESPONJA MEDULAR; DOENCA GLOMERULOCISTICO; CISTOS SIMPLES; DOENCA RENAL CISTICA; FENOMENO DE LIESEGANG; CISTO ECHINOCOCCAL; ENDOMETRIOSE RENAL; DOENCAS INFLAMATORIAS RENAIS; TUBERCULOSE RENAL; PIELONEFRITE; NECROSE PAPILAR; PIELONEFRITE XANTOGRANULOMATOSA; NEFRITE INTERSTICIAL MEGALOCITICA; MALAKOPLAKIA CORTICAL RENAL; PSEUDOTUMOR MIOFIBROBLASTICO INFLAMATORIO; DISTURBIOS NEOPLASICOS; NEFROBLASTOMATOSE; TUMOR DE WILM'S; NEFROMA MESOBLASTICO CONGENITO; SARCOMA DE CELULAS CLARAS; TUMOR MALIGNO RABDOIDE; ADENOMA METANEFRICO; ADENOFIBROMA METANEFRICO; TUMOR ESTROMAL METANEFRICO; ONCOCITOMA; ADENOMA PAPILAR DO RIM; CARCINOMA DE CELULAS RENAIS; NEOPLASIAS NEUROENDOCRINAS DO RIM; TUMOR CARCINOIDE; CARCINOMA NEUROENDOCRINO DE CELULAS PEQUENAS; TUMOR NEUROECTODERMICO PRIMITIVO; SARCOMA DE EWING; PARAGANGLIOMA; FEOCROMOCITOMA; NEUROBLASTOMA; NEOPLASIAS MESENQUIMAIS; ANGIOMIOLIPOMA; ANGIOMIOLIPOMA EPITELIOIDE; LEIOMIOMA; TUMOR DE CELULAS JUSTAGLOMERULARES; RENINOMA; TUMOR DE CELULAS INTERSTICIAIS RENOMEDULAR; HEMANGIOMA; LINFANGIOMA; LIPOMA; TUMOR FIBROSO SOLITARIO; TUMOR GLOMICO; SCHWANNOMA; LEIOMIOSARCOMA; HISTIOCITOMA; LIPOSARCOMA; FIBROSARCOMA; HEMANGIOPERICITOMA; OSTEOSARCOMA; ANGIOSARCOMA; CONDROSARCOMA; TUMOR MISTO EPITELIAL E ESTROMAL; NEFROMA CISTICO; SARCOMA SINOVIAL; PLASMACITOMA; LINFOMA MALIGNO; LEUCEMIA; NEOPLASIAS DE CELULAS GERMINATIVAS; METASTASE; HIPERPLASIA ADENOMATOIDE DO EPITELIO DA CAPSULA DE BOWMAN

303/697US=21 / Patologia
Petersen RO, Sesterhenn IA, Davis CJ. Renal pelvis and ureter. In: ___. Urologic pathology. 3rd ed. Philadelphia: Lippincott Willians & Wilkins, 2009. p. 133-74. ISBN 978-0-7817-5343-2.

PELVE RENAL; URETER; DIVERTICULO CALYCEAL; DIVERTICULO URETERAL; OBSTRUCAO DA JUNCAO URETEROPELVICA; AGENESIA URETERAL; URETER DUPLICADO; URETER ECTOPICO; URETEROCELE; VALVULA URETERAL CONGENITA; MEGAURETER; HIPERPLASIA UROTELIAL; URETERITE CISTICA; URETERITE GLANDULAR; METAPLASIA ESCAMOSA; ADENOMA NEFROGENICO; METAPLASIA NEFROGENICA; LESOES HAMARTOMATOSOS; POLIPOS FIBROEPITELIAIS; HEMATOMA SUBMUCOSO; CALCIFICACAO SUBMUCOSA; AMILOIDOSE; DISTURBIOS VASCULARES; DISTURBIOS INFLAMATORIOS; INFECCAO FUNGICA; PIELITE INCRUSTADO; URETERITE; ESQUISTOSSOMOSE; GRANULOMA DE CELULAS PLASMATICAS; MALAKOPLAKIA; SARCOIDOSE; GRANULOMATOSE DE WEGENER; ENDOMETRIOSE URETERAL; PAPILOMA; PAPILOMA INVERTIDO; ADENOMA VILOSO; CARCINOMA UROTELIAL; CARCINOMA CELULAS ESCAMOSAS; CARCINOMA VERRUCOSO; ADENOCARCINOMA; CARCINOMA DE CELULAS PEQUENAS; TUMORES CARCINOIDES; NEOPLASIAS MESENQUIMAIS BENIGNAS; NEOPLASIAS MESENQUIMAIS MALIGNAS; LINFOMA MALIGNO; FIBROSE RETEROPERITONEAL

304/697US=22 / Urologia
Bukowski RM, Figlin RA, Motzer RJ. Targeted therapy for metastatic renal cell carcinoma: overview. In: ___. Renal cell carcinoma: molecular targets and clinical applications. 2ªed. New York: Humana Press, 2009. p. 1-12. ISBN 978-1-58829-737-2.

CARCINOMA DE CELULAS RENAIS; VHL GENE; PROTEINA VHL; VEGF; PDGF; TERAPIAS RCC

305/697US=22 / Urologia
Dhanani N, Vocke C, Bratslavsky G, Linehan WM. Molecular genetics in inherited renal cell carcinoma: identification of targets in the hereditary syndromes. In: Bukowski RM, Figlin RA, Motzer RJ. Renal cell carcinoma: molecular targets and clinical applications. 2ªed. New York: Humana Press, 2009. p. 13-33. ISBN 978-1-58829-737-2.

NEOPLASIAS DE RIM; HIPPLE CON-LINDAU; BHD; BIRT-HOGG-DUBE; FUMARATO HIDRATASE

306/697US=22 / Urologia
Zhou M. Molecular targets in renal tumors: pathologic assessment. In: Bukowski RM, Figlin RA, Motzer RJ. Renal cell carcinoma: molecular targets and clinical applications. 2ªed. New York: Humana Press, 2009. p. 35-48. ISBN 978-1-58829-737-2.

CARCINOMA DE CELULAS RENAIS; NEOPLASIA RENAL PATOLOGIA; CITOGENETICA; PROGNOSTICO

307/697US=22 / Urologia
Hutson TE, Thakkar S, Cohen P, Borden EC. Interferons and interleukin-2: molecular basis of activity and therapeutic results. In: Bukowski RM, Figlin RA, Motzer RJ. Renal cell carcinoma: molecular targets and clinical applications. 2ªed. New York: Humana Press, 2009. p. 49-78. ISBN 978-1-58829-737-2.

INTERFERON; INTERLEUCINA; IFN-X2, IL-2; INIBICAO DA ANGIOGENESE; EFEITOS CLINICOS DA IL-2 E IFN

308/697US=22 / Urologia
Junior Kaelin WG, Geoge DJ. The molecular biology of kidney cancer and its clinical translation into treatment strategies. In: Bukowski RM, Figlin RA, Motzer RJ. Renal cell carcinoma: molecular targets and clinical applications. 2ªed. New York: Humana Press, 2009. p. 79-97. ISBN 978-1-58829-737-2.

VON HIPPEL-LINDAU; HIPOXIA; ANGIOGENESE; HIF; VEGF; KDR; MTOR

309/697US=22 / Urologia
Rathmell WK, Rini BI. VEGF: biologic aspects and clinical approaches. In: Bukowski RM, Figlin RA, Motzer RJ. Renal cell carcinoma: molecular targets and clinical applications. 2ªed. New York: Humana Press, 2009. p. 99-118. ISBN 978-1-58829-737-2.

RCC; VEGF; VHL; BEVACIZUMAB; BEVACIZUMABE

310/697US=22 / Urologia
Lam JS, Figlin RA, Belldegrum AS,. VEGF: and PDGF receptors: biologic relevance and clinical approaches to inhibition. In: Bukowski RM, Figlin RA, Motzer RJ. Renal cell carcinoma: molecular targets and clinical applications. 2ªed. New York: Humana Press, 2009. p. 119-49. ISBN 978-1-58829-737-2.

DERIVADO DE PLAQUETAS FACTOR DE CRESCIMENTO; RECEPTORES; TRANSDUCAO DE SINAL; TIROSINA-QUINASE; FACTOR DE CRESCIMENTO ENDOTELIAL VASCULAR

311/697US=22 / Urologia
Motzer RJ. Sunitinib and axitinib in renal cell carcinoma. In: Bukowski RM, Figlin RA, Motzer RJ. Renal cell carcinoma: molecular targets and clinical applications. 2ªed. New York: Humana Press, 2009. p. 151-65. ISBN 978-1-58829-737-2.

SUNITINIB; SU11248; AXITINIBE; CARCINOMA DE CELULAS RENAIS; SUTENT; AG-013736

312/697US=22 / Urologia
George S, Bukowski RM. Sorafenib in renal cell carcinoma. In: Bukowski RM, Figlin RA, Motzer RJ. Renal cell carcinoma: molecular targets and clinical applications. 2ªed. New York: Humana Press, 2009. p. 167-87. ISBN 978-1-58829-737-2.

CARCINOMA DE CELULAS RENAIS; SORAFENIB; INIBIDOR DE TIROSINA CINASE; VEGF; TERAPIA ANTIANGIOGENICA

313/697US=22 / Urologia
Rini BI. Additional tyrosine kinase inhibitors in renal cell carcinoma. In: Bukowski RM, Figlin RA, Motzer RJ. Renal cell carcinoma: molecular targets and clinical applications. 2ªed. New York: Humana Press, 2009. p. 189-93. ISBN 978-1-58829-737-2.

INIBIDORES VEGF; TKI; PTK787; AZD2171; ZK222584; INIBIDOR DE TIROSINA CINASE; PAZOPANIB

314/697US=22 / Urologia
Ramakrishnan V, Bhaskar V, Fox M, Wilson K, Cheville JC, Finck BA. Integrin &*945;5&*946;1 as a noveltherapeutic target in renal cancer. In: Bukowski RM, Figlin RA, Motzer RJ. Renal cell carcinoma: molecular targets and clinical applications. 2ªed. New York: Humana Press, 2009. p. 195-209. ISBN 978-1-58829-737-2.

INTEGRINAS NA ANGIOGENESE; TERAPIA ANTI-ANGIOGENICA; CANCER RENAL &*945;5&*946;1; VOLOCIXIMAB

315/697US=22 / Urologia
Shuch B, Belldegrun AS, Figlin RA. Carbonic anhydrase IX: biology and clinical approaches. In: Bukowski RM, Figlin RA, Motzer RJ. Renal cell carcinoma: molecular targets and clinical applications. 2ªed. New York: Humana Press, 2009. p. 211-29. ISBN 978-1-58829-737-2.

CAIX; CCR CELULA CLARA; INTERLEUCINA-2 RESPOSTA; PROGNOSTICO; G250

316/697US=22 / Urologia
Oosterwijk-Wakka JC, Boerman OC, Mulders PFA, Oosterwijk E. Monoclonal antibody G250 recognizing carbonic anhydrase IX in renal cell carcinoma: biological and clinical studies. In: Bukowski RM, Figlin RA, Motzer RJ. Renal cell carcinoma: molecular targets and clinical applications. 2ªed. New York: Humana Press, 2009. p. 231-47. ISBN 978-1-58829-737-2.

ANTICORPO MONOVLONAL; G250; IMUMUNOTHERAPY

317/697US=22 / Urologia
Reckamp KL, Figlin RA, Strieter RM. Chemokines in renal cell carcinoma: implications for tumor angiogenesis and metastasis. In: Bukowski RM, Figlin RA, Motzer RJ. Renal cell carcinoma: molecular targets and clinical applications. 2ªed. New York: Humana Press, 2009. p. 249-65. ISBN 978-1-58829-737-2.

CARCINOMA DE CELULAS RENAIS; QUIMIOCINAS; ANGIOGENESE; POTENCIAL METASTATICO; TRATAMENTO

318/697US=22 / Urologia
Cho D, Mier JW, Atkins MB. PI3K/AKt/mTOR pathway: a growth and proliferation pathway. In: Bukowski RM, Figlin RA, Motzer RJ. Renal cell carcinoma: molecular targets and clinical applications. 2ªed. New York: Humana Press, 2009. p. 267-85. ISBN 978-1-58829-737-2.

INIBIDORES PI3K; RCC; HIPERATIVACAO DO AKT/PI3K; ATIVIDADE AKT; TEMSIROLIMUS

319/697US=22 / Urologia
Jonasch E, Walker CL. EGFR and HER2: relevance in renal cell carcinoma. In: Bukowski RM, Figlin RA, Motzer RJ. Renal cell carcinoma: molecular targets and clinical applications. 2ªed. New York: Humana Press, 2009. p. 287-303. ISBN 978-1-58829-737-2.

CARCINOMA DE CELULAS RENAIS; ERBB; TERAPIA-ALVO; RESISTENCIA; SINALIZACAO

320/697US=22 / Urologia
Garcia JA, Varizi SJA, Ganapathi R. Proteasome-NFkB signaling pathway: relevance in RCC. In: Bukowski RM, Figlin RA, Motzer RJ. Renal cell carcinoma: molecular targets and clinical applications. 2ªed. New York: Humana Press, 2009. p. 305-20. ISBN 978-1-58829-737-2.

SISTEMA UBIQUITINA-PROTEASSOMA; VIA DE PROTEASSOMA NA RCC; INIBICAO DO PROTEASSOMA

Primeira | Anterior | Próxima | Última